Topics Flashcards
Treatment Considerations in Polycythemia Vera and Myelofibrosis: A Real-World Patient Case Discussion
Branded Combo
Intervening with Jakafi® (ruxolitinib) to Achieve Durable Count Control: Real-World Patient Case Discussion
Branded PV
Intervening With Jakafi® (ruxolitinib) at Diagnosis in Patients With Intermediate- or High-Risk Myelofibrosis | A Real World Patient Case Discussion
Branded MF
Consider Jakafi ® (ruxolitinib) At the First Sign of Steroid-Refractory Acute GVHD
GVHD
Intervening With Jakafi® (ruxolitinib) to Achieve Durable Count Control—Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea
Virtual Abridged Branded PV
Intervening With Jakafi® (ruxolitinib) at Diagnosis in Patients With Intermediate- or High-Risk Myelofibrosis
Virtual Abridged Branded MF
AN IN-DEPTH REVIEW:
Long-Term Findings From COMFORT-II, a Phase 3 Study of Ruxolitinib vs Best Available Therapy for Myelofibrosis
Journal Article Review: COMFORT 5 year
AN IN-DEPTH REVIEW:
Ruxolitinib Versus Standard Therapy for the Treatment of Polycythemia Vera
Journal Article Review: Response 1
AN IN-DEPTH REVIEW: Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly (RESPONSE-2) a Randomised Open-Label, Phase 3b Study
Journal Article Review: Response 2
Identifying Patients With Clinical Characteristics of Advanced Polycythemia Vera— Real-World Patient Case Discussion
Unbranded PV
Identifying Patients With Clinical Characteristics of Advanced Polycythemia Vera
Virtual Abridged Unbranded PV
Intervening With Ruxolitinib at Diagnosis in Patients With Intermediate- or High-Risk Myelofibrosis - Real-World Patient Case Discussion
Inst. Branded MF
Intervening With Ruxolitinib to Achieve Durable Count Control: Real-World Patient Case Discussion - Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea
Inst. Branded PV
AN IN-DEPTH REVIEW OF THE REACH2 STUDY PUBLICATION: Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Journal Article Review: REACH2
AN IN-DEPTH REVIEW: Long-Term Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Polycythaemia Vera (RESPONSE): 5-Year Follow Up of a Phase 3 Study
Journal Article Review: RESPONSE 5
Identifying Patients With Clinical Characteristics of Advanced Polycythemia Vera— Real-World Patient Case Discussion
Inst. Unbranded PV
PEMAZYRE® (pemigatinib): The First and Only FDA-Approved Treatment for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma (CCA) with an FGFR2 Fusion or Rearrangement
PEMAZYRE
Monjuvi (tafasitamab-cxix) for Use as Second-Line Therapy in Adult Patients with R/R DLBCL, in Combination with Lenalidomide
Monjuvi
Consider Jakafi® (ruxolitinib) At the First Sign of Steroid-Refractory Acute GVHD In adult and pediatric patients 12 years and older”
ABR GVHD
Intervening With Ruxolitinib at Diagnosis in Patients With Intermediate- or High-Risk Myelofibrosis | Real-World Patient Case Discussion
Thyne - Branded MF
Intervening With Ruxolitinib to Achieve Durable Count Control: Real-World Patient Case Discussion - Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea
Thyne - Branded PV
Monitoring Patients With Polycythemia Vera for Potential Characteristics of Disease Progression— Real-World Patient Case Discussion
Thyne - Unbranded PV
